Literature DB >> 15260940

Anxiety disorders and schizophrenia.

Jacqueline E Muller1, Liezl Koen, Seedat Soraya, Robin A Emsley, Daniel J Stein.   

Abstract

Anxiety symptoms and disorders have long been described in schizophrenia. This article reviews the epidemiology, phenomenology, and neurobiologic underpinnings of comorbid anxiety symptoms and disorders in schizophrenia. Recent literature was obtained by Medline searches using key words relating to schizophrenia and anxiety symptoms or disorders. There is some evidence that anxiety may be a core symptom dimension in schizophrenia, although further work is required. There is evidence that comorbid obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, and social anxiety disorder are all more common than expected by chance in schizophrenia, although additional work is needed to determine the mechanisms that underlie these associations and their clinical implications. In the interim, however, the data emphasize the importance of assessing and treating comorbid anxiety symptoms and disorders in schizophrenia.

Entities:  

Mesh:

Year:  2004        PMID: 15260940     DOI: 10.1007/s11920-004-0074-0

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   8.081


  64 in total

1.  Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.

Authors:  Michael Poyurovsky; Rena Kurs; Abraham Weizman
Journal:  J Clin Psychiatry       Date:  2003-05       Impact factor: 4.384

Review 2.  Developing effective treatments for posttraumatic disorders among people with severe mental illness.

Authors:  S D Rosenberg; K T Mueser; M J Friedman; P G Gorman; R E Drake; R M Vidaver; W C Torrey; M K Jankowski
Journal:  Psychiatr Serv       Date:  2001-11       Impact factor: 3.084

3.  Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

Authors:  R A Emsley; P P Oosthuizen; A F Joubert; M C Roberts; D J Stein
Journal:  J Clin Psychiatry       Date:  1999-11       Impact factor: 4.384

4.  Obsessive-compulsive disorder in patients with first-episode schizophrenia.

Authors:  M Poyurovsky; C Fuchs; A Weizman
Journal:  Am J Psychiatry       Date:  1999-12       Impact factor: 18.112

Review 5.  Anxiety and the schizophrenic process: clinical and epidemiological evidence.

Authors:  G Turnbull; P Bebbington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2001-05       Impact factor: 4.328

6.  Trauma exposure and posttraumatic stress disorder in psychosis: findings from a first-admission cohort.

Authors:  Yuval Neria; Evelyn J Bromet; Sylvia Sievers; Janet Lavelle; Laura J Fochtmann
Journal:  J Consult Clin Psychol       Date:  2002-02

7.  Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey.

Authors:  K S Kendler; T J Gallagher; J M Abelson; R C Kessler
Journal:  Arch Gen Psychiatry       Date:  1996-11

8.  Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

Authors:  W Wolfgang Fleischhacker; Mariëlle Eerdekens; Keith Karcher; Gary Remington; Pierre-Michel Llorca; Wlodzimierz Chrzanowski; Stephen Martin; Ola Gefvert
Journal:  J Clin Psychiatry       Date:  2003-10       Impact factor: 4.384

9.  Trauma and posttraumatic stress disorder in people with schizophrenia.

Authors:  Sandra G Resnick; Gary R Bond; Kim T Mueser
Journal:  J Abnorm Psychol       Date:  2003-08

10.  Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine.

Authors:  I Berman; B L Sapers; H H Chang; M F Losonczy; J Schmildler; A I Green
Journal:  J Clin Psychopharmacol       Date:  1995-06       Impact factor: 3.153

View more
  10 in total

1.  Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.

Authors:  José L Moreno; Mitsumasa Kurita; Terrell Holloway; Javier López; Richard Cadagan; Luis Martínez-Sobrido; Adolfo García-Sastre; Javier González-Maeso
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

Review 2.  Endophenotypes in Schizophrenia for the Perinatal Period: Criteria for Validation.

Authors:  Randal G Ross; Robert Freedman
Journal:  Schizophr Bull       Date:  2015-05-04       Impact factor: 9.306

3.  Long Noncoding RNA-Directed Epigenetic Regulation of Gene Expression Is Associated With Anxiety-like Behavior in Mice.

Authors:  Paola A Spadaro; Charlotte R Flavell; Jocelyn Widagdo; Vikram S Ratnu; Michael Troup; Chikako Ragan; John S Mattick; Timothy W Bredy
Journal:  Biol Psychiatry       Date:  2015-02-11       Impact factor: 13.382

4.  Unemployment, homelessness, and other societal outcomes in patients with schizophrenia: a real-world retrospective cohort study of the United States Veterans Health Administration database : Societal burden of schizophrenia among US veterans.

Authors:  Dee Lin; Hyunchung Kim; Keiko Wada; Maya Aboumrad; Ethan Powell; Gabrielle Zwain; Carmela Benson; Aimee M Near
Journal:  BMC Psychiatry       Date:  2022-07-08       Impact factor: 4.144

5.  Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms.

Authors:  Daniel Fulford; Tara A Niendam; Erin G Floyd; Cameron S Carter; Daniel H Mathalon; Sophia Vinogradov; Barbara K Stuart; Rachel L Loewy
Journal:  Schizophr Res       Date:  2013-04-12       Impact factor: 4.939

6.  Separating scale-free and oscillatory components of neural activity in schizophrenia.

Authors:  Frigyes Samuel Racz; Kinga Farkas; Orestis Stylianou; Zalan Kaposzta; Akos Czoch; Peter Mukli; Gabor Csukly; Andras Eke
Journal:  Brain Behav       Date:  2021-02-03       Impact factor: 2.708

7.  Discerning undifferentiated anxiety from syndromal anxiety in acute-phase schizophrenia.

Authors:  Kalai Naidu; Werdie van Staden; Lizelle Fletcher
Journal:  Ann Gen Psychiatry       Date:  2020-04-15       Impact factor: 3.455

8.  State anxiety influences P300 and P600 event-related potentials over parietal regions in the hollow-mask illusion experiment.

Authors:  Vasileios Ioakeimidis; Nareg Khachatoorian; Corinna Haenschel; Thomas A Papathomas; Attila Farkas; Marinos Kyriakopoulos; Danai Dima
Journal:  Personal Neurosci       Date:  2021-02-16

9.  Reduced Slc1a1 expression is associated with neuroinflammation and impaired sensorimotor gating and cognitive performance in mice: Implications for schizophrenia.

Authors:  Parisa Afshari; Wei-Dong Yao; Frank A Middleton
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

10.  Dispositional Mindfulness and Psychotic Symptoms in Schizophrenia Spectrum Disorders: The Mediating Roles of Rumination and Negative Emotion.

Authors:  Angie Ho Yan Lam; Yee Tak Derek Cheung; Kwan Ho Wong; Sau Fong Leung; Wai Tong Chien
Journal:  Neuropsychiatr Dis Treat       Date:  2022-01-11       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.